 | • レポートコード：GIR-23F3953 • 出版社/出版日：GlobalInfoResearch / 2023年2月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、75ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Tysabri (natalizumab) Drug Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界のTysabri（ナタリズマブ）医薬品の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 Tysabri（ナタリズマブ）医薬品市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・多発性硬化症、クローン病 アプリケーション別セグメントは次のように区分されます。 ・病院、ドラッグストア 世界のTysabri（ナタリズマブ）医薬品市場の主要なマーケットプレーヤーは以下のとおりです。 ・Biogen 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - Tysabri（ナタリズマブ）医薬品の概要 - タイプ別分析（2017年vs2021年vs2028年）：多発性硬化症、クローン病 - アプリケーション別分析（2017年vs2021年vs2028年）：病院、ドラッグストア - 世界のTysabri（ナタリズマブ）医薬品市場規模・予測 - 世界のTysabri（ナタリズマブ）医薬品生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Biogen ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：多発性硬化症、クローン病 ・アプリケーション別分析2017年-2028年：病院、ドラッグストア ・Tysabri（ナタリズマブ）医薬品の北米市場分析 - Tysabri（ナタリズマブ）医薬品の北米市場：タイプ別市場規模2017年-2028年 - Tysabri（ナタリズマブ）医薬品の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・Tysabri（ナタリズマブ）医薬品のヨーロッパ市場分析 - ：Tysabri（ナタリズマブ）医薬品のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：Tysabri（ナタリズマブ）医薬品のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・Tysabri（ナタリズマブ）医薬品のアジア太平洋市場分析 - Tysabri（ナタリズマブ）医薬品のアジア太平洋市場：タイプ別市場規模2017年-2028年 - Tysabri（ナタリズマブ）医薬品のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・Tysabri（ナタリズマブ）医薬品の南米市場分析 - Tysabri（ナタリズマブ）医薬品の南米市場：タイプ別市場規模2017年-2028年 - Tysabri（ナタリズマブ）医薬品の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・Tysabri（ナタリズマブ）医薬品の中東・アフリカ市場分析 - Tysabri（ナタリズマブ）医薬品の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - Tysabri（ナタリズマブ）医薬品の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Tysabri (natalizumab) Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Tysabri (natalizumab) Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Tysabri (natalizumab) Drug global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Multiple Sclerosis segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Tysabri (natalizumab) Drug include Biogen, , , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Tysabri (natalizumab) Drug market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Multiple Sclerosis
Crohn’s Disease
Market segment by Application can be divided into
Hospital
Drugs Stores
The key market players for global Tysabri (natalizumab) Drug market are listed below:
Biogen
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tysabri (natalizumab) Drug product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Tysabri (natalizumab) Drug, with price, sales, revenue and global market share of Tysabri (natalizumab) Drug from 2019 to 2022.
Chapter 3, the Tysabri (natalizumab) Drug competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tysabri (natalizumab) Drug breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Tysabri (natalizumab) Drug market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Tysabri (natalizumab) Drug.
Chapter 13, 14, and 15, to describe Tysabri (natalizumab) Drug sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Tysabri (natalizumab) Drug Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Tysabri (natalizumab) Drug Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Multiple Sclerosis
1.2.3 Crohn’s Disease
1.3 Market Analysis by Application
1.3.1 Overview: Global Tysabri (natalizumab) Drug Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Drugs Stores
1.4 Global Tysabri (natalizumab) Drug Market Size & Forecast
1.4.1 Global Tysabri (natalizumab) Drug Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Tysabri (natalizumab) Drug Sales in Volume (2017-2028)
1.4.3 Global Tysabri (natalizumab) Drug Price (2017-2028)
1.5 Global Tysabri (natalizumab) Drug Production Capacity Analysis
1.5.1 Global Tysabri (natalizumab) Drug Total Production Capacity (2017-2028)
1.5.2 Global Tysabri (natalizumab) Drug Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Tysabri (natalizumab) Drug Market Drivers
1.6.2 Tysabri (natalizumab) Drug Market Restraints
1.6.3 Tysabri (natalizumab) Drug Trends Analysis
2 Manufacturers Profiles
2.1 Biogen
2.1.1 Biogen Details
2.1.2 Biogen Major Business
2.1.3 Biogen Tysabri (natalizumab) Drug Product and Services
2.1.4 Biogen Tysabri (natalizumab) Drug Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Tysabri (natalizumab) Drug Breakdown Data by Manufacturer
3.1 Global Tysabri (natalizumab) Drug Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Tysabri (natalizumab) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Tysabri (natalizumab) Drug
3.4 Market Concentration Rate
3.4.1 Top 3 Tysabri (natalizumab) Drug Manufacturer Market Share in 2021
3.4.2 Top 6 Tysabri (natalizumab) Drug Manufacturer Market Share in 2021
3.5 Global Tysabri (natalizumab) Drug Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Tysabri (natalizumab) Drug Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Tysabri (natalizumab) Drug Market Size by Region
4.1.1 Global Tysabri (natalizumab) Drug Sales in Volume by Region (2017-2028)
4.1.2 Global Tysabri (natalizumab) Drug Revenue by Region (2017-2028)
4.2 North America Tysabri (natalizumab) Drug Revenue (2017-2028)
4.3 Europe Tysabri (natalizumab) Drug Revenue (2017-2028)
4.4 Asia-Pacific Tysabri (natalizumab) Drug Revenue (2017-2028)
4.5 South America Tysabri (natalizumab) Drug Revenue (2017-2028)
4.6 Middle East and Africa Tysabri (natalizumab) Drug Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Tysabri (natalizumab) Drug Sales in Volume by Type (2017-2028)
5.2 Global Tysabri (natalizumab) Drug Revenue by Type (2017-2028)
5.3 Global Tysabri (natalizumab) Drug Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Tysabri (natalizumab) Drug Sales in Volume by Application (2017-2028)
6.2 Global Tysabri (natalizumab) Drug Revenue by Application (2017-2028)
6.3 Global Tysabri (natalizumab) Drug Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Tysabri (natalizumab) Drug Sales by Type (2017-2028)
7.2 North America Tysabri (natalizumab) Drug Sales by Application (2017-2028)
7.3 North America Tysabri (natalizumab) Drug Market Size by Country
7.3.1 North America Tysabri (natalizumab) Drug Sales in Volume by Country (2017-2028)
7.3.2 North America Tysabri (natalizumab) Drug Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Tysabri (natalizumab) Drug Sales by Type (2017-2028)
8.2 Europe Tysabri (natalizumab) Drug Sales by Application (2017-2028)
8.3 Europe Tysabri (natalizumab) Drug Market Size by Country
8.3.1 Europe Tysabri (natalizumab) Drug Sales in Volume by Country (2017-2028)
8.3.2 Europe Tysabri (natalizumab) Drug Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Tysabri (natalizumab) Drug Sales by Type (2017-2028)
9.2 Asia-Pacific Tysabri (natalizumab) Drug Sales by Application (2017-2028)
9.3 Asia-Pacific Tysabri (natalizumab) Drug Market Size by Region
9.3.1 Asia-Pacific Tysabri (natalizumab) Drug Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Tysabri (natalizumab) Drug Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Tysabri (natalizumab) Drug Sales by Type (2017-2028)
10.2 South America Tysabri (natalizumab) Drug Sales by Application (2017-2028)
10.3 South America Tysabri (natalizumab) Drug Market Size by Country
10.3.1 South America Tysabri (natalizumab) Drug Sales in Volume by Country (2017-2028)
10.3.2 South America Tysabri (natalizumab) Drug Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Tysabri (natalizumab) Drug Sales by Type (2017-2028)
11.2 Middle East & Africa Tysabri (natalizumab) Drug Sales by Application (2017-2028)
11.3 Middle East & Africa Tysabri (natalizumab) Drug Market Size by Country
11.3.1 Middle East & Africa Tysabri (natalizumab) Drug Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Tysabri (natalizumab) Drug Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Tysabri (natalizumab) Drug and Key Manufacturers
12.2 Manufacturing Costs Percentage of Tysabri (natalizumab) Drug
12.3 Tysabri (natalizumab) Drug Production Process
12.4 Tysabri (natalizumab) Drug Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Tysabri (natalizumab) Drug Typical Distributors
13.3 Tysabri (natalizumab) Drug Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Tysabri (natalizumab) Drug Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Tysabri (natalizumab) Drug Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Biogen Basic Information, Manufacturing Base and Competitors
Table 4. Biogen Major Business
Table 5. Biogen Tysabri (natalizumab) Drug Product and Services
Table 6. Biogen Tysabri (natalizumab) Drug Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Global Tysabri (natalizumab) Drug Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 8. Global Tysabri (natalizumab) Drug Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 9. Market Position of Manufacturers in Tysabri (natalizumab) Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 10. Global Tysabri (natalizumab) Drug Production Capacity by Company, (K Units): 2020 VS 2021
Table 11. Head Office and Tysabri (natalizumab) Drug Production Site of Key Manufacturer
Table 12. Tysabri (natalizumab) Drug New Entrant and Capacity Expansion Plans
Table 13. Tysabri (natalizumab) Drug Mergers & Acquisitions in the Past Five Years
Table 14. Global Tysabri (natalizumab) Drug Sales by Region (2017-2022) & (K Units)
Table 15. Global Tysabri (natalizumab) Drug Sales by Region (2023-2028) & (K Units)
Table 16. Global Tysabri (natalizumab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 17. Global Tysabri (natalizumab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 18. Global Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 19. Global Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 20. Global Tysabri (natalizumab) Drug Revenue by Type (2017-2022) & (USD Million)
Table 21. Global Tysabri (natalizumab) Drug Revenue by Type (2023-2028) & (USD Million)
Table 22. Global Tysabri (natalizumab) Drug Price by Type (2017-2022) & (USD/Unit)
Table 23. Global Tysabri (natalizumab) Drug Price by Type (2023-2028) & (USD/Unit)
Table 24. Global Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 25. Global Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 26. Global Tysabri (natalizumab) Drug Revenue by Application (2017-2022) & (USD Million)
Table 27. Global Tysabri (natalizumab) Drug Revenue by Application (2023-2028) & (USD Million)
Table 28. Global Tysabri (natalizumab) Drug Price by Application (2017-2022) & (USD/Unit)
Table 29. Global Tysabri (natalizumab) Drug Price by Application (2023-2028) & (USD/Unit)
Table 30. North America Tysabri (natalizumab) Drug Sales by Country (2017-2022) & (K Units)
Table 31. North America Tysabri (natalizumab) Drug Sales by Country (2023-2028) & (K Units)
Table 32. North America Tysabri (natalizumab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 33. North America Tysabri (natalizumab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 34. North America Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 35. North America Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 36. North America Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 37. North America Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 38. Europe Tysabri (natalizumab) Drug Sales by Country (2017-2022) & (K Units)
Table 39. Europe Tysabri (natalizumab) Drug Sales by Country (2023-2028) & (K Units)
Table 40. Europe Tysabri (natalizumab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 41. Europe Tysabri (natalizumab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 42. Europe Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 43. Europe Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 44. Europe Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 45. Europe Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 46. Asia-Pacific Tysabri (natalizumab) Drug Sales by Region (2017-2022) & (K Units)
Table 47. Asia-Pacific Tysabri (natalizumab) Drug Sales by Region (2023-2028) & (K Units)
Table 48. Asia-Pacific Tysabri (natalizumab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 49. Asia-Pacific Tysabri (natalizumab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 50. Asia-Pacific Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 51. Asia-Pacific Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 52. Asia-Pacific Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 53. Asia-Pacific Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 54. South America Tysabri (natalizumab) Drug Sales by Country (2017-2022) & (K Units)
Table 55. South America Tysabri (natalizumab) Drug Sales by Country (2023-2028) & (K Units)
Table 56. South America Tysabri (natalizumab) Drug Revenue by Country (2017-2022) & (USD Million)
Table 57. South America Tysabri (natalizumab) Drug Revenue by Country (2023-2028) & (USD Million)
Table 58. South America Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 59. South America Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 60. South America Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 61. South America Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 62. Middle East & Africa Tysabri (natalizumab) Drug Sales by Region (2017-2022) & (K Units)
Table 63. Middle East & Africa Tysabri (natalizumab) Drug Sales by Region (2023-2028) & (K Units)
Table 64. Middle East & Africa Tysabri (natalizumab) Drug Revenue by Region (2017-2022) & (USD Million)
Table 65. Middle East & Africa Tysabri (natalizumab) Drug Revenue by Region (2023-2028) & (USD Million)
Table 66. Middle East & Africa Tysabri (natalizumab) Drug Sales by Type (2017-2022) & (K Units)
Table 67. Middle East & Africa Tysabri (natalizumab) Drug Sales by Type (2023-2028) & (K Units)
Table 68. Middle East & Africa Tysabri (natalizumab) Drug Sales by Application (2017-2022) & (K Units)
Table 69. Middle East & Africa Tysabri (natalizumab) Drug Sales by Application (2023-2028) & (K Units)
Table 70. Tysabri (natalizumab) Drug Raw Material
Table 71. Key Manufacturers of Tysabri (natalizumab) Drug Raw Materials
Table 72. Direct Channel Pros & Cons
Table 73. Indirect Channel Pros & Cons
Table 74. Tysabri (natalizumab) Drug Typical Distributors
Table 75. Tysabri (natalizumab) Drug Typical Customers
List of Figures
Figure 1. Tysabri (natalizumab) Drug Picture
Figure 2. Global Tysabri (natalizumab) Drug Revenue Market Share by Type in 2021
Figure 3. Multiple Sclerosis
Figure 4. Crohn's Disease
Figure 5. Global Tysabri (natalizumab) Drug Revenue Market Share by Application in 2021
Figure 6. Hospital
Figure 7. Drugs Stores
Figure 8. Global Tysabri (natalizumab) Drug Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Tysabri (natalizumab) Drug Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Tysabri (natalizumab) Drug Sales (2017-2028) & (K Units)
Figure 11. Global Tysabri (natalizumab) Drug Price (2017-2028) & (USD/Unit)
Figure 12. Global Tysabri (natalizumab) Drug Production Capacity (2017-2028) & (K Units)
Figure 13. Global Tysabri (natalizumab) Drug Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Tysabri (natalizumab) Drug Market Drivers
Figure 15. Tysabri (natalizumab) Drug Market Restraints
Figure 16. Tysabri (natalizumab) Drug Market Trends
Figure 17. Global Tysabri (natalizumab) Drug Sales Market Share by Manufacturer in 2021
Figure 18. Global Tysabri (natalizumab) Drug Revenue Market Share by Manufacturer in 2021
Figure 19. Tysabri (natalizumab) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Tysabri (natalizumab) Drug Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Tysabri (natalizumab) Drug Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Tysabri (natalizumab) Drug Sales Market Share by Region (2017-2028)
Figure 23. Global Tysabri (natalizumab) Drug Revenue Market Share by Region (2017-2028)
Figure 24. North America Tysabri (natalizumab) Drug Revenue (2017-2028) & (USD Million)
Figure 25. Europe Tysabri (natalizumab) Drug Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Tysabri (natalizumab) Drug Revenue (2017-2028) & (USD Million)
Figure 27. South America Tysabri (natalizumab) Drug Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Tysabri (natalizumab) Drug Revenue (2017-2028) & (USD Million)
Figure 29. Global Tysabri (natalizumab) Drug Sales Market Share by Type (2017-2028)
Figure 30. Global Tysabri (natalizumab) Drug Revenue Market Share by Type (2017-2028)
Figure 31. Global Tysabri (natalizumab) Drug Price by Type (2017-2028) & (USD/Unit)
Figure 32. Global Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 33. Global Tysabri (natalizumab) Drug Revenue Market Share by Application (2017-2028)
Figure 34. Global Tysabri (natalizumab) Drug Price by Application (2017-2028) & (USD/Unit)
Figure 35. North America Tysabri (natalizumab) Drug Sales Market Share by Type (2017-2028)
Figure 36. North America Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 37. North America Tysabri (natalizumab) Drug Sales Market Share by Country (2017-2028)
Figure 38. North America Tysabri (natalizumab) Drug Revenue Market Share by Country (2017-2028)
Figure 39. United States Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Tysabri (natalizumab) Drug Sales Market Share by Type (2017-2028)
Figure 43. Europe Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 44. Europe Tysabri (natalizumab) Drug Sales Market Share by Country (2017-2028)
Figure 45. Europe Tysabri (natalizumab) Drug Revenue Market Share by Country (2017-2028)
Figure 46. Germany Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Tysabri (natalizumab) Drug Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Tysabri (natalizumab) Drug Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Tysabri (natalizumab) Drug Revenue Market Share by Region (2017-2028)
Figure 55. China Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Tysabri (natalizumab) Drug Sales Market Share by Type (2017-2028)
Figure 62. South America Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 63. South America Tysabri (natalizumab) Drug Sales Market Share by Country (2017-2028)
Figure 64. South America Tysabri (natalizumab) Drug Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Tysabri (natalizumab) Drug Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Tysabri (natalizumab) Drug Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Tysabri (natalizumab) Drug Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Tysabri (natalizumab) Drug Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Tysabri (natalizumab) Drug Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Tysabri (natalizumab) Drug in 2021
Figure 76. Manufacturing Process Analysis of Tysabri (natalizumab) Drug
Figure 77. Tysabri (natalizumab) Drug Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source
| 【Tysabri（ナタリズマブ）医薬品について】 Tysabri（ナタリズマブ）は、主に多発性硬化症（MS）とクローン病の治療に用いられる生物学的製剤です。ナタリズマブは、特定の免疫系細胞の働きを抑制し、病気の進行を遅らせる作用を持っています。この医薬品は、特に免疫系が神経系に攻撃を行うことで問題を引き起こす病状において、その効果が注目されています。 ナタリズマブの定義としては、これはヒトモノクローナル抗体に分類される薬剤であり、体内のインテグリンという接着分子に結合します。この作用により、白血球が血管から神経組織への移動を妨げ、炎症を引き起こす細胞の侵入を防ぎます。結果として、神経組織の損傷が軽減され、症状の悪化を抑えることが可能となります。 ナタリズマブの特徴的な点は、その特異性と効果の持続性です。多発性硬化症においては、再発の頻度を著しく低下させることが臨床試験で確認されており、その有効性が期待されています。一方、クローン病においても、炎症の抑制によって症状の軽減を得ることができます。ナタリズマブの投与は通常、他の治療法が効果を示さない場合に検討されます。 この薬剤の主な用途は、多発性硬化症とクローン病に限られず、他にもいくつかの自己免疫疾患や神経疾患に対する研究が進められています。ナタリズマブは通常、年齢や既往歴に応じた厳格な基準を満たす患者に対して投与され、定期的な検査が必要となります。これにより、副作用や減少した効果に対するモニタリングが行われます。 ナタリズマブの関連技術としては、バイオテクノロジーとモノクローナル抗体の研究が挙げられます。ナタリズマブは、細胞培養技術や遺伝子工学の進展により開発された薬剤であり、これらの技術が生物学的製剤の効能向上に寄与しています。現在も新たな治療法の開発が継続されており、ナタリズマブの適応症やその作用に関する研究が深まっています。 副作用として、ナタリズマブにはいくつかのリスクが伴います。特に、PML（進行性多発性白質脳症）という重篤なウイルス感染症が報告されており、このリスクは治療を受ける患者の中でも特に注意が必要です。投与開始前、及び治療中には、医師の指導の下でリスク評価が行われ、定期的にMRI検査が推奨されることがあります。 ナタリズマブの投与は、通常は月に一度の静注によって行われます。この治療法は、患者が自宅で自己管理することが難しいため、医療機関での定期的な受診が必要です。また、ナタリズマブを使用する場合は、治療の開始時および継続中に、感染症の兆候に敏感になる必要があります。これにより、早期に適切な対策を講じることが可能となります。 最後に、ナタリズマブは使用に関する倫理的見地からも議論されています。特に、治療の有効性とリスクのバランス、患者の生活の質への影響を考慮しなければなりません。医療者と患者の間で十分なコミュニケーションを行い、理解と合意を得ることが、治療の成功に繋がります。 以上が、Tysabri（ナタリズマブ）に関する概要です。この医薬品は、多発性硬化症やクローン病の患者にとって重要な治療選択肢の一つであり、その効果とリスクについての理解が進むことで、より良い治療結果が得られることが期待されています。今後も関連する研究や開発が進むことを願っています。 |